Reassuring data on use of blood pressure medications in COVID-19 patients

+Practice

HEARTBEAT

Reassuring data on use of blood pressure medications in COVID-19 patients

3 June 2020

Chris Ellis

Wednesday 3 June 2020, 02:03 PM

Patients might be concerned about what they read and hear in the news regarding the use of renin–angiotensin system blockers during the COVID-19 pandemic. Cardiologist Chris Ellis reviews recent research and current recommendations

Key points, A letter published in March hypothesised that ACE inhibitors and angiotensin II receptor blockers might increase the risk of developing severe and fat, Pract Green w Pale Yellow

COVID-19

Cardiovascular

Research

References

1. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8(4):e21.
2. Zhang P, Zhu L, Cai J, et al. Association of inpatient use ofangiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020; 17 April online.
3. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2224–60.

How to Treat

+How to treat

FREE READ

COPD: Prevent, treat and comfort

Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management

Wednesday 26 March 2025, 12:50 AM